Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
Delayed Quote. Delayed Nyse - 09/24 04:10:00 pm
73.61 USD   +0.77%
09/24Health Care Stocks Retreat Friday
MT
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09/24Health Care Stocks Slip Pre-Bell Friday
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
71.93(c) 71.97(c) 72.04(c) 73.05(c) 73.61(c) Last
15 989 368 11 995 904 9 028 738 12 813 485 14 706 242 Volume
+0.35% +0.06% +0.10% +1.40% +0.77% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 46 881 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 16,1x
Yield 2021 3,52%
Sales 2022 50 655 M - -
Net income 2022 15 506 M - -
Net Debt 2022 10 724 M - -
P/E ratio 2022 12,6x
Yield 2022 3,82%
Capitalization 186 B 186 B -
EV / Sales 2021 4,30x
EV / Sales 2022 3,89x
Nbr of Employees 73 500
Free-Float 70,7%
More Financials
Company
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Ratings of Merck & Co., Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about MERCK & CO., INC.
09/24Health Care Stocks Retreat Friday
MT
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09/24Health Care Stocks Slip Pre-Bell Friday
MT
09/24MERCK : LYNPARZA« (olaparib) in Combination With Abiraterone Significantly Delayed Disease..
BU
09/24ASTRAZENECA : Merck & Co.'s Combination Therapy Benefits Prostate Cancer Patients in Phase..
MT
09/24ASTRAZENECA : Merck & Co.'s Prostate Cancer Drug Extends Lives in Late-Stage Study
MT
09/21MERCK : Thinking about trading options or stock in Draftkings, Merck, ConocoPhillips, Walg..
PR
09/21MERCK : Building Sustainable Value for our Business and Society
PU
09/20MERCK : KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Ris..
AQ
09/20MERCK : KEYTRUDA (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Che..
AQ
09/20MERCK : KEYTRUDA (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in P..
AQ
09/20MERCK : Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination With..
AQ
09/19MERCK : KEYTRUDA« (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Ch..
BU
09/19Merck’s Keytruda« Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as..
CI
09/18MERCK : KEYTRUDA« (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Ri..
BU
More news
News in other languages on MERCK & CO., INC.
09/24Les actions du secteur de la santé reculent vendredi
09/24MERCK : résultats encourageants dans le cancer de la prostate
09/24La thérapie combinée d'AstraZeneca, Merck & Co. est bénéfique pour les patients atteint..
09/24MERCK, ROCHE, SHIONOGI : la course aux traitements Covid sous forme de pilule
09/24PLANÈTE BOURSE : La revue de presse du vendredi 24 septembre 2021
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,61 $
Average target price 93,42 $
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.01%186 334
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037